"KNT-127: A Novel Delta Opioid Receptor Agonist for Anxiety Modulation"
A study published in Neuropsychopharmacology Reports reveals the potential of delta opioid receptors to alleviate anxiety through the activation of a specific brain pathway. The selective DOP agonist, KNT-127, was found to reduce anxiety-like behavior in mice, offering promise for developing new treatments for anxiety-related disorders. The study's methodology, anchored in optogenetics, targeted a neural pathway from the prelimbic cortex to the basolateral nucleus of the amygdala, critical areas associated with emotion regulation and anxiety development. The findings underscore the pivotal role of this brain circuit in regulating innate anxiety and demonstrate the potential of DOP agonists, like KNT-127, in alleviating anxiety.
